Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis

Bibliography

• ROWLAND LP, SCHNEIDER N: Amyotrophic lateral sclerosis. New. Engl. J. Med. (2001) 344(22):1691-1700.
   Google Scholar
• ROWLAND LP: How amyotrophic lateral sclerosis got its name. Arch. Neurol. (2001) 58:512-515.
   PubMed Web of Science ®Google Scholar
• BROOKS BR: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J. Neurol. Sci. (1994) 124(s):96-107.
   PubMed Web of Science ®Google Scholar
• HOUSEHAM E, SWASH M: Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? J. Neurol. Sci. (2000) 180:76-81.
   PubMed Web of Science ®Google Scholar
• CHIO A: ISIS survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J. Neurol. (1999) 246(SIII):1-5.
   Google Scholar
• CHIO A: Update on ISI survey: europe, north america and south america. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2000) 1(S1):9-11.
   PubMed Web of Science ®Google Scholar
• SWINGLER RJ, FRASER H, WARLOW CP: Motor neuron disease and polio in Scotland. JNNP (1992) 55:1116-1120.
   PubMed Web of Science ®Google Scholar
• TRAYNOR BJ, CODD MB, CORR B, FORDE C, FROST BA, HARDIMAN O: Incidence and prevalence of ALS in Ireland, 1995-1997. Neurology (1999) 52:504.
   PubMed Web of Science ®Google Scholar
• PARALS: Incidence of ALS in Italy. Neurology (2001) 56:239-244.
   PubMed Web of Science ®Google Scholar
• LOGROSCINO G, BEGHI E, ZOCCOLELLA S et al.: Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. JNNP (2005) 76:1094-1098.
   PubMed Web of Science ®Google Scholar
• NEARY D, SNOWDEN JS, MANN D: Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). J. Neurol. Sci. (2000) 180:15-20.
   PubMed Web of Science ®Google Scholar
• ZOCCOLELLA SG, PALAGANO G, FRADDOSIO A et al.: ALS-plus: 5 cases of concomitant amyotrophic lateral sclerosis and parkinsonism. Neurol. Sci. (2004) 23(s2):123-124.
   Web of Science ®Google Scholar
• DEL AGUILA MA, LONGSTRETH WT JR, MCGUIRE V, KOEPSELL TD, VAN BELLE G: Prognosis in amyotrophic lateral sclerosis. A population-based study. Neurology (2003) 60:813-819.
   PubMed Web of Science ®Google Scholar
• MILLUL A, BEGHI E, LOGROSCINO G, MICHELI A, VITELLI E, ZARDI A: Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology (2005) 25(3):114-119.
   PubMed Web of Science ®Google Scholar
• GROHME K, MARAVIC MV, GASSER T, BORASIO GD: A case of amyotrophic lateral sclerosis with very slow progression over 44 years. Neuromuscul. Disord. (2001) 11(4):414-416.
   PubMed Web of Science ®Google Scholar
• PUGLIATTI M, ROSATI G, CARTON H: The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol (2006) 13:700-722.
   PubMed Web of Science ®Google Scholar
• JOHNSON CA, STANTON BR, TURNER MR et al.: Amyotrophic lateral sclerosis in an urban setting: a population based study of innner city london. J. Neurol. (2006) 253:1642-1643.
   PubMed Web of Science ®Google Scholar
• ANDERSEN P: Amyotrophic lateral sclerosis genetics with mendelian inheritance. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London UK (2006):187-208.
   Google Scholar
• MAJOR-KRAKAUER D, WILLEMS PJ, HOFMAN A: Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet. (2003) 63(2):83-101.
   PubMed Web of Science ®Google Scholar
• BRUIJN L, CUDKOWICZ M: Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev. Neurotherapeutics (2006) 6(3):417-428.
   PubMedGoogle Scholar
• YANG Y, HENTATI A, DENG H et al.: The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. (2001) 29:160-165.
   PubMed Web of Science ®Google Scholar
• Hadano S, Hand C, Osuga H et al.: A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. (2001) 29:166-173.
   PubMed Web of Science ®Google Scholar
• HENTATI A, OUAHCHI K, PERICAK-VANCE MA et al.: Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics (1998) 2(1):55-60.
   PubMed Web of Science ®Google Scholar
• HONG S, BROOKS SR, HUNG W et al.: X-linked dominant locus for late-onset familial amyotrophic lateral sclerosis. Soc. Neurosci. Abst. (1998) 24:478.
   Google Scholar
• JULIEN J, KRIZ J: Transgenic mouse models of amyotrophic lateral sclerosis. Biochemimica et Biophysica Acta (2006) 1762:1013-1024.
   PubMed Web of Science ®Google Scholar
• BOILLEE S, VANDE VELDE C, CLEVELAND D: ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron (2006) 52:39-59.
   PubMed Web of Science ®Google Scholar
• ALEXANDER MD, TRAYNOR BJ, MILLER N et al.: “True” sporadic als associated with a novel SOD-1 mutation. Ann. Neurol. (2002) 52(5):680-683.
   PubMed Web of Science ®Google Scholar
• SIMPSON C, AL-CHALABI A: Amyotrophic lateral sclerosis as a complex genetic disease. Biochimica et Biophysica Acta (2006) 1762:973-985.
   PubMed Web of Science ®Google Scholar
• ISHIGAKI S, NIWA J, ANDO Y et al.: Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett. (2002) 531:354-358.
   PubMed Web of Science ®Google Scholar
• SCHYMICK J, SCHATZ S, HON-CHUNG F et al.: Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. (2007) 6(4):322-328.
   PubMed Web of Science ®Google Scholar
• TANAKA F, JIANG YM, YAMAMOTO M et al.: Gene expresión profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. (2006) 7(S1):9.
   Google Scholar
• SARIS C, VAN VUGHT P, YIGITTOP H et al.: Molecular pathway analysis of amyotrophic lateral sclerosis by genome-wide expression profiling of human blood. Amyotroph. Lateral Scler. (2006) 7(S1):11.
   Google Scholar
• PLATO CC, GARRUTO RM, GALASK D et al.: Amyotrophic lateral sclerosis–parkinsonism–dementia complex of Guam: changing incidence rates during the past 60 years. Am. J. Epidemiol. (2003) 157:149-157.
   PubMed Web of Science ®Google Scholar
• SUNDAR P, CHANG-EN Y, WEIVA S et al.: Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum. Mol. Genet. (2007) 16(3):295-306.
   PubMed Web of Science ®Google Scholar
• COX PA, SACKS OW: Cycad neurotoxin, consumption of flying foxes, and ALS/PDC disease in guam. Neurology (2002) 58:956-959.
   PubMed Web of Science ®Google Scholar
• KWANG C, CRAIG U, LEE C et al.: Cycad neurotoxin, consumption of flying foxes, and ALS/PDC disease in guam. Neurology (2002) 59:1664-1665.
   PubMedGoogle Scholar
• CHO A, BENZI G, DOSSENA M et al.: Severely increased risk for amyotrophic lateral sclerosis among Italian professional football players. Brain (2005) 128:472-476.
   PubMed Web of Science ®Google Scholar
• WEISSKOPF M, O'REILLY E, MCCULLOUGH M et al.: Prospective study of military service and risk of amyotrophic lateral sclerosis. Neurology (2005) 64:32-37.
   PubMed Web of Science ®Google Scholar
• HALEY RW: Excess incidence of ALS in young Gulf War veterans. Neurology (2003) 61:750-756.
   PubMed Web of Science ®Google Scholar
• HORNER RD, KAMINS KG, FEUSSNER JR et al.: Excess incidence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology (2003) 61:742-749.
   PubMed Web of Science ®Google Scholar
• NELSON L, MCGUIRE V: Epidemiology of amyotrophic lateral sclerosis. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London UK (2006):25-42.
   Google Scholar
• MCGUIRE V, LONGSTRETH W, KOEPSELL T, VAN BELLE G: Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology (1996) 12:219-228.
   Web of Science ®Google Scholar
• MILLER RG, MOORE DH, GELINAS D et al.: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology (2001) 56:843-848.
   PubMed Web of Science ®Google Scholar
• DESNUELLE C, DIB M, GARREL C et al.: A double-blind, placebo-controlled trial of a-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. (2001) 2:9-18.
   PubMed Web of Science ®Google Scholar
• SHEFNER J, CUDKOWICZ M, SCHOENFELD D et al.: A clinical trial of creatine in ALS. Neurology (2004) 63:1656-1661.
   PubMed Web of Science ®Google Scholar
• CUDKOWICZ M, SHEFNER J, SCHOENFELD D et al.: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 61:456-464.
   PubMed Web of Science ®Google Scholar
• CUDKOWICZ M, SHEFNER J, SCHOENFELD D et al.: Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. (2006) 60:22-31.
   PubMed Web of Science ®Google Scholar
• LAU J, CONWIT R, MILLER R, CUDKOWICZ M: Therapeutic trials in amyotrophic lateral sclerosis: past, present, future. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London, UK (2006):335-356.
   Google Scholar
• BENOIT E, ESCANDE D: Riluzole specifically blocks inactivated Na channels in myelinated nerve fiber. Pflugers Arch. (1991) 419:603-609.
   PubMed Web of Science ®Google Scholar
• ZONA C, SINISCALCHI A, MERCURI NB et al.: Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience (1998) 85:931-938.
   PubMed Web of Science ®Google Scholar
• STEFANI A, SPADONI F, BERNARDINI G: Differential inhibition by riluzole, lamotrigine and phenytoin of sodium and potassium currents in cultured rat cortical neurons. Neuroscience (1998) 85:931-938.
   PubMed Web of Science ®Google Scholar
• GURNEY ME, FLECK TJ, HIMES CS, HALL ED: Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology (1998) 50(1):62-66.
   PubMed Web of Science ®Google Scholar
• BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Eng. J. Med. (1994) 330:585-591.
   PubMed Web of Science ®Google Scholar
• LACOMBLEZ L, BENSIMON G, LEIGH P et al.: Dose ranging study of riluzole in amyotrophic lateral sclerosis. Lancet (1996) 347:1425-1431.
   PubMed Web of Science ®Google Scholar
• SORENSON E: An acute, life-threatening, hypersensitivity reaction to riluzole. Neurology (2006) 67:2260-2261.
   PubMed Web of Science ®Google Scholar
• PONGRATZ D, NEUNDORFER B, FISCHER W: German open label trial of riluzole 50mg b.i.d. in amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. (2000) 180:82-85.
   PubMed Web of Science ®Google Scholar
• OLIVER D, BORASIO G: Palliative care and quality of life in amyotrophic lateral sclerosis. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare London UK (2006):357-362.
   Google Scholar
• VAN DEN BERG JP, KALMIJN S, LINDEMAN E et al.: Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology (2005) 65(8):1264-1267.
   PubMed Web of Science ®Google Scholar
• MILLER RG, ROSENBERG JA, GELINAS DF et al.: Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence based review), report of the quality standards subcommittee of the american academy of neurology: als practice parameters task force. Neurology (1999) 52(7):1311-1323.
   PubMed Web of Science ®Google Scholar
• LEIGH N, ABRAHAMS S, AL-CHALABI A et al.: The management of motor neurone disease. J. Neurol. Neurosurg. Psychiatry (2003) 74:32-47.
   Web of Science ®Google Scholar
• ENG D: Management guidelines for motor neurone disease patients on non-invasive ventilation at home. Palliat. Med. (2006) 20:69-79.
   PubMed Web of Science ®Google Scholar
• MAZZINI L, CORRA T, ZACCALA M, MORA G, DEL PIANO M, GALANTE M: Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. Neurology (1995) 242:695-698.
   Web of Science ®Google Scholar
• ABOUSSOUAN LS, KHAN SU, MEEKER DP, STELMACH K, MITSUMOTO H: Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann. Intern. Med. (1997) 127:450-453.
   PubMed Web of Science ®Google Scholar
• TRAYNOR BJ, ALEXANDER M, CORR B, FROST E, HARDIMAN O: Effect of a multidisciplinary amyotrophic (ALS) clinic on ALS survival: a population based registry 1996-2000. J. Neurol. Neurosurg. Psychiatry (2003) 74(9):1258-1261.
   PubMed Web of Science ®Google Scholar
• ANDERSEN PM: Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr. Neurol. Neurosci. Rep. (2006) 6(1):37-46.
   PubMed Web of Science ®Google Scholar
• CLEMENT AM, NGUYEN MD, ROBERTS EA et al.: Wild-type non-neuronal cells extend survival of SOD-1 mutant motor neurons in ALS mice. Science (2003) 302:113-117.
   PubMed Web of Science ®Google Scholar
• BOILEE S, YAMANAKA K, LOBSIGER C et al.: Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 312:1389-1392.
   PubMed Web of Science ®Google Scholar
• YOSHIHARA T, ISHIGAKI S, YAMAMOTO M et al.: Differential expression of inflammation-and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. (2002) 80:158-167.
   PubMed Web of Science ®Google Scholar
• FERRAIULO L, HEATH P, HOLDEN H et al.: Gene expression profile of spinal motor neurons in the G93A SOD1 mouse model of ALS at different time points. Amyotroph. Lateral Scler. (2006) 7(S1):10.
   Google Scholar
• KUDO L, KARSTEN S, WIEDAU-PAZOS M: Whole genome microarray analysis of motor neuron vulnerability in G93A-SOD1 and P301L-Tau transgenic mouse models of als. Amyotroph. Lateral Scler. (2001) 7(S1):10.
   Google Scholar
• BARBER S, MEAD R, SHAW P: Oxidative stress in als: a mechanism of neurodegeneration and a therapeutic target. Biochimica et Biophysica Acta (2006) 1762:1051-1067.
   PubMed Web of Science ®Google Scholar
• RYU H, SMITH K, CAMELO S et al.: Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. (2005) 93(5):1087-1098.
   PubMed Web of Science ®Google Scholar
• BRUIJN L, HOUSEWEART MK, KATO S et al.: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science (1998) 281:1851-1854.
   PubMed Web of Science ®Google Scholar
• DURHAM HD, ROY J, DONG L, FIGLEWICZ DA: Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. (1997) 56:523-530.
   PubMed Web of Science ®Google Scholar
• CLEVELAND DW, LIU J: Oxidation versus aggregation - how do SOD1 mutants cause ALS? Nat. Med. (2000) 6:1320-1321.
   PubMed Web of Science ®Google Scholar
• JOHNSTON J, DALTON M, GURNEY M, KOPITO R: Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA (2000) 97:12571-12576.
   PubMed Web of Science ®Google Scholar
• WANG J, XU G, SLUNT HH: Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. Neurobiol. Dis. (2005) 20:943-952.
   PubMed Web of Science ®Google Scholar
• SATO T, NAKANISHI T, YAMAMOTO Y et al.: Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology (2001) 65:1954-1957.
   Google Scholar
• VAN DEN BOSCH L, VAN DAMME P, BOGAERT E, ROBBERECHT W: The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochimica et Biophysica Acta (2006) 1762:1068-1082.
   PubMed Web of Science ®Google Scholar
• ALEXANDER G, DEITCH J, SEEBURGER J, DEL VALLE L, HEIMAN-PATTERSON T: Elevated cortical extracellular fluid glutamate in transgenic mice expressing human mutant (G93A) superoxide dismutase. J. Neurochem. (2000) 74:1666-1673.
   PubMed Web of Science ®Google Scholar
• SHAW P, FORREST V, RICHARDSON J, WASTELL H: CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration (1995) 4:209-216.
   PubMedGoogle Scholar
• COURATIER P, HUGON J,SINDOU P, VALLAT J, DUMAS M: Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet (1993) 341:265-268.
   PubMed Web of Science ®Google Scholar
• SPENCER P, ROY D, LUDOLPH A, HUGON J, DWIVEDI M, SCHAUMBURG H: Lathyrism: evidence for role of the neuroexcitatory amino acid BOAA. Lancet (1986) 2:1066-1067.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD, VAN KAMMEN M, LEVEY A et al.: Selective loss of glutamate transporter GLT-1 in ALS. Ann. Neurol. (1995) 38:73-84.
   Web of Science ®Google Scholar
• ROTHSTEIN JD, PATEL S,REGAN MR et al.: β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 433:73-77.
   PubMed Web of Science ®Google Scholar
• TATENO M, SADAKATA H, TANAKA M et al.: Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum. Mol. Genet. (2004) 13:2183-2196.
   PubMed Web of Science ®Google Scholar
• MANFREDI G, BEAL M: Mitochondrial dysfunction and energy metabolism in amyotrophic lateral sclerosis. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London UK (2006):323-331.
   Google Scholar
• KONG J, XU Z: Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. (1998) 18:3241-3250.
   PubMed Web of Science ®Google Scholar
• KIRBY J, HALLIGAN E, BAPTISTA M et al.: Mutant SOD1 alters the motor neuron transcriptase: implications for familial ALS. Brain (2005) 128:1686-1706.
   PubMed Web of Science ®Google Scholar
• MOISSE K, STRONG M: Innate immunity in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta (2006) 1762:1083-1093.
   PubMed Web of Science ®Google Scholar
• ALEXIANU M, KOZOVSKA M, APPEL S: Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 57:1282.
   PubMed Web of Science ®Google Scholar
• DRACHMAN D, ROTHSTEIN J: Inhibition of cyclooxygenate-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann. Neurol. (2000) 48(5):792-795.
   PubMed Web of Science ®Google Scholar
• URUSHITANI M, SILK A, SAKURAI T, NUKINA N,TAKAHASHI R, JULIEN J: Chromogranin-median secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. (2005) 9:108-118.
   PubMed Web of Science ®Google Scholar
• XIAO S, MCLEAN J, ROBERTSON J: Neuron intermediate filaments and ALS: a new look at an old question. Biochimica et Biophysica Acta (2006) 1762:1001-1012.
   PubMed Web of Science ®Google Scholar
• AL-CHALABI A, ANDERSEN P, NILSSON P et al. : Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Mol. Genet. (1999) 8:157-164.
   PubMed Web of Science ®Google Scholar
• PULS I, JONNAKUTY C, LAMONTE B et al.: Mutant dynactin in motor neuron disease. Nat. Genet. (2003) 33:455-456.
   PubMed Web of Science ®Google Scholar
• STERNECK E, KAPLAN DR, JOHNSON P: Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J. Neurochem. (1996) 67:1365.
   PubMed Web of Science ®Google Scholar
• CHEVALIER-LARSEN E, HOLZBAUR E: Axonal transport and neurodegenerative disease. Biochimica et Biophysica Acta (2006) 1762:1094-1108.
   PubMed Web of Science ®Google Scholar
• EKESTERN E: Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener. Dis. (2004) 1:88-100.
   PubMed Web of Science ®Google Scholar
• STORKEBAUM E, LAMBRECHTS D, DEWERCHIN M et al.: Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. (2004) 8:85-92.
   PubMed Web of Science ®Google Scholar
• SENDTNER M: Damaging secretions: chromogranins team up with mutant SOD1. Nat. Neurosci. (2006) 9:12-14.
   PubMed Web of Science ®Google Scholar
• LI M, ONA VO, GUEGAN C et al.: Functional role of caspase 1 and 3 in ALS. Science (2000) 288:335-339.
   PubMed Web of Science ®Google Scholar
• SPOOREN W, HENGERER B: DNA laddering and caspase 3-like activity in the spinal cord of a mouse model of familial amyotrophic lateral sclerosis. Cell Mol. Biol. (2000) 46:63.
   PubMed Web of Science ®Google Scholar
• MARTIN LJ: Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution to a programmed cell death mechanism. J. Neuropathol. Exp. Neurol. (1999) 58:459-471.
   PubMed Web of Science ®Google Scholar
• HE B, STRONG M: Motor neuronal death in sporadic amyotrophic lateral sclerosis (ALS) is not apoptotic: a comparative study of ALS and chronic aluminum chloride neurotoxicity in new Zealand white rabbits. Neuropathol. Appl. Neurobiol. (2000) 26:150-160.
   PubMed Web of Science ®Google Scholar
• TRAYNOR BJ, BRUIJN L, CONWIT F et al.: Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology (2006) 67:20-27.
   PubMed Web of Science ®Google Scholar
• SHOEMAKER JL, SEELY KA, REED R, CROW P, PRATHER L: The cb2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Atlanta USA Society for Neuroscience Meeting (2006).
   Google Scholar
• SMITH RA, MILLER TM, YAMANAKA K et al.: Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin.Invest. (2006) 116(8):2290-2297.
   PubMed Web of Science ®Google Scholar
• CUDKOWICZ M, SHEFNER M, SIMPSON E et al.: A multicenter, dose ranking safety and pharmacokinetic study of arimoclomol in ALS. Amyotrophic Lateral Sclerosis (2006) 7(S1):113.
   Google Scholar
• KIPIANI K, KIAEI M, CHEN J, CALINGASAN N, BEAL M: Celasterol blocks motor neuron cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. (2004) 90(S1):92.
   Google Scholar
• MATTHEWS RT, YANG L, BROWNE S, BAIK M, BEAL M: Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA (1998) 95:8892-8897.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN J: Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann. Neurol. (2003) 53:423-426.
   PubMed Web of Science ®Google Scholar
• GROENVELD G, VELDINK J, VAN DER TWEEL I et al.: A randomized, sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. (2003) 53:437-445.
   PubMed Web of Science ®Google Scholar
• KLIVENYI P, KIAEI M, GARDIAN G et al.: Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of ALS. J. Neurochem. (2004) 88:576-582.
   PubMed Web of Science ®Google Scholar
• KIM S, KIM H, KOH S et al.: Effectiveness of recombinant human erythropoietin therapy in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. (2006) 7(S1):9.
   Google Scholar
• BLAIR M, PEASE M, HAMMOND J et al.: Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Investig. Ophthalmol. and Vis. Sci. (2005) 46:884-890.
   PubMed Web of Science ®Google Scholar
• GORDON PH, DOORISH C, MONTES J et al.: Randomized, controlled phase II trial of glatiramer acetate in ALS. Neurology (2006) 66:1117-1119.
   PubMed Web of Science ®Google Scholar
• PITZER C, KRUGER C, KIRSCH F et al.: G-CSF protects motoneurons and counteracts denervation atrophy in a mouse model of ALS. Atlanta USA Society for Neuroscience Meeting (2006).
   Google Scholar
• AOKI M, ISHIGAKI I, NAGAI M et al.: Intrathecal delivery of hepatocyte growth factor at the onset of paralysis slows disease progression in a rat model of ALS. Amyotrophic Lateral Sclerosis (2006) 7(S1):41.
   Google Scholar
• FUNAKOSHI H, NAKAMURA T: Hepatocyte growth factor as a novel neurotrophic factor for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. (2006) 7(S1):41.
   Google Scholar
• BEDLACK R: A pilot trial of levetiracetam for cramps, spasticity and neuroprotection in patients with motor neuron disease. Northeast ALS Consortium Meeting.Boston USA (2006).
   Google Scholar
• SMITH K: The effects of levetiracetam on the sod-1 mutant mouse model of amyotrophic lateral sclerosis/motor neuron disease. Unpublished data on file at UCB Pharma.
   Google Scholar
• YOSHINO H, KIMURA A: Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. (2006) 7:241-245.
   PubMed Web of Science ®Google Scholar
• POMPL P, HO L, BIANCHI M et al.: A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. (2003) 17:725-727.
   PubMed Web of Science ®Google Scholar
• CUDKOWICZ ME, ANDRES PI, SCHOENFELD D et al.: Saftey and dose escalating study of oral sodium phenylbutyrate in subjects with ALS. Amyotroph. Lateral Scler. (2006) 7(S1):9.
   Google Scholar
• DANZEISEN R, SCHWALENSTOECKER B, GILLARDON F et al.: Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its non-dopaminergic enantiomer SND919CL2x. J. Pharm. Exp. Therap. (2006) 316:189-199.
   PubMed Web of Science ®Google Scholar
• LORENZL S, NARR S, ANGELE B et al.: The matrix metalloproteinase inhibitor Ro 26-2853 extends survival in transgenic ALS mice. Exp. Neurol. (2006) 200:166-171.
   PubMed Web of Science ®Google Scholar
• XU L, YAN J, Chen D et al.: Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation (2006) 82:865-875.
   PubMed Web of Science ®Google Scholar
• KIAEI M, PETRI S, KIPIANI K et al.: Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. (2006) 26:2467-2473.
   PubMed Web of Science ®Google Scholar
• ABITBOL J, CUVIER V, BORDET T, DROUOT C, BERNA P, PRUSS R: Safety and pharmacokinetics of repeated doses of TRO-19622, a drug candidate for the treatment of amyotrophic lateral sclerosis and spinal muscular atrophy. Amyotroph. Lateral Scler. (2006) 7(S1):9.
   Google Scholar
• SUGAI F, YAMAMOTO Y, MIYAGUCHI K et al.: Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. (2004) 20:3179-3183.
   PubMed Web of Science ®Google Scholar
• BENATAR M, POLAK M, KAPLAN S, GLASS J: Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible? J. Neurol. Sci. (2004) 251:3-9.
   Web of Science ®Google Scholar
• PASINETTI G, UNGAR L,LANGE J et al.: Identification of potential CSF biomarkers in ALS. Neurology (2006) 66:1218-1222.
   PubMed Web of Science ®Google Scholar
• CHEUNG Y, GORDON P, LEVIN B: Selecting promising ALS therapies in clinical trials. Neurology (2006) 67:1748-1751.
   PubMed Web of Science ®Google Scholar
• ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutations in CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59-62.
   PubMed Web of Science ®Google Scholar
• HAND CK, KHORIS J, SALACHAS F et al.: A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. Am. J. Hum. Genet. (2002) 70:251-256.
   PubMed Web of Science ®Google Scholar
• CHANCE P, RABIN B, RYAN S et al.: Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am. J. Hum. Genet. (62):633-640.
   PubMedGoogle Scholar
• ABALKHAIL H, MITCHELL J, HABGOOD J, ORRELL R, DE BELLEROCHE J: A new familial amyotrophic lateral sclerosis locus on chromosome 16q12.1-16q12.2. Am.J. Hum. Genet. (2003) 73:383-389.
   PubMed Web of Science ®Google Scholar
• SAPP P, HOSLER B, MCKENNA-YASEK D et al.: Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am. J. Hum. Genet. (2003) 73:397-403.
   PubMed Web of Science ®Google Scholar
• NISHIMURA A, MITNE-NETO M, SILVA H et al.: A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. (2004) 75:822-831.
   PubMed Web of Science ®Google Scholar
• GREENWAY MJ, ALEXANDER MD, ENNIS S et al.: A novel candidate region for ALS on chromosome 14q11.2. Neurology (2004) 63:1936-1938.
   PubMed Web of Science ®Google Scholar
• GREENWAY M, ANDERSEN P, RUSS C et al.: ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nat. Genet. (2006) 38:411-413.
   PubMed Web of Science ®Google Scholar
• MOMENI P, SCHYMICK J, JAIN S et al.: Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol. (2006) 6:44.
   PubMed Web of Science ®Google Scholar
• MORITA M, AL-CHALABI A, ANDERSEN P et al.: A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology (2006) 66:839-844.
   PubMed Web of Science ®Google Scholar
• HUTTON M, LENDON C, RIZZU P et al.: Association of missense and 5′splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 393:702-705.
   PubMed Web of Science ®Google Scholar
• WOOD JD, BEAUJEUX TP, SHAW PJ: Protein aggregation in motor neurone disorders. Neuropathol. Appl. Neurobiol. (2003) 29:529-545.
   PubMed Web of Science ®Google Scholar
• ROSS C, POIRIER M: Protein aggregation and neurodegenerative disease. Nat. Med. (2004) 10(s):S10-S17.
   PubMed Web of Science ®Google Scholar
• STRONG M, KESAVAPANY S, PANT H: The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J. Neuropathol.Exp. Neurol. (2005) 64:649-664.
   PubMed Web of Science ®Google Scholar